Ebola virus from Mali blood sample
Infectious disease scientists report early development of a potential universal vaccine for Ebola viruses that preclinical tests show might neutralize all four species of these deadly viruses infecting people in recent outbreaks, mainly in Africa.
Scientists at Cincinnati Children’s report their preclinical results in the Journal of Virology, published by the American Society for Microbiology ahead of print publication on May 9.
Although still in early preclinical testing, researchers report that their data indicate that the prospective vaccine has potential to be a stand-alone protection from Ebola. It also could broaden and extend the durability of protective immunity induced by current live vaccines already being tested in clinical trials against individual Ebola virus species, said Karnail Singh, PhD, the study’s co-principal investigator in the Division of Infectious Diseases.
“This could be a significant advancement in the global effort to prevent or manage Ebola outbreaks, especially if this vaccine used alone or in combination with another Ebola vaccine results in long-term and durable protective immunity against different Ebola viruses,” Singh said.
A deadly Ebola outbreak in West Africa between 2013 and 2016 accelerated international efforts to develop vaccines for these highly infectious and harmful viruses. This led to development of recombinant Ebola vaccines in which glycoprotein from Zaire Ebola virus is engineered into another modified live viral vector. When administered, these live vaccines induce immune responses against the Ebola glycoprotein that, in turn, protect against any subsequent attack by the Ebola virus.
Singh and colleagues report that while the live-vector vaccines are producing encouraging results in clinical trials, until the current study none of the new vaccines under development have been shown to induce immune responses that cross-react against multiple Ebola virus species that cause the deadly disease in humans.
A DIFFERENT APPROACH
The new vaccine takes a novel approach, according to the study. The researchers designed a bivalent, spherical Ebola virus-like particle (VLP) that incorporates two genetically diverse glycoproteins (one each from the Zaire Ebola virus and Sudan Ebola virus) on a spherical core. This approach will not cause illness in the recipient as the VLPs lack the genetic material and do not multiply. The vaccine works by stimulating immune responses against Ebola that generate virus-fighting antibodies to attack the different virus species.
When the researchers administered their new Ebola VLP vaccine to appropriate animal models, it produced robust immune responses against Ebola virus species known to be pathogenic in humans.
Although the new vaccine uses glycoproteins from two Ebola virus species, Singh said it might work against all four known pathogenic Ebola viruses as responses to one of the glycoproteins generates cross-reactive responses against two other Ebola virus species.
MORE TESTING NEEDED
The researchers emphasize that extensive additional preclinical testing of the prospective Ebola VLP vaccine is needed before it could potentially be tested in clinical trials.
A key collaborator on the multi-institutional study — which included the University of Cincinnati College of Medicine, the Emory University School of Medicine, and the University of Louisiana’s New Iberia Research Center – was Paul Spearman, MD, Director, Division of Infectious Diseases at Cincinnati Children’s.
Spearman said at the moment, vaccine challenge experiments are in the planning stages. They will involve working in collaboration with an institution that has Level 4 biosafety facilities and will require additional external funding to move this promising research forward.
“If the data from those studies is equally encouraging, the vaccine should be ready to progress to generation of clinical grade material for human trials,” he said.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Ebola vaccine
- Marburg Virus Outbreak: 10 facts about the Ebola-like virus
Ghana is racing against time to contain the outbreak of one of the highly lethal viruses in human history. Two people in the southern part of Ghana tested positive for the Marburg virus. The ...
- GeoVax Labs Shares Rise 13% After Positive Study Results for Ebolavirus Vaccine
By Chris Wack GeoVax Labs Inc. shares were 13% higher at $2.04 after a peer-reviewed animal efficacy study of its modified vaccine Ankara vectored ...
- Promising Marburg vaccine yet to be tested on humans due to lack of funding
Oxford University’s Professor Teresa Lambe, the designer of the vaccine, fears Marburg disease is ‘now being seen in places where it’s never been seen before’ ...
- Ebola 2.0? Ghana Confirms First Outbreak of Deadly Marburg Virus
In previous outbreaks, case fatality rates for Marburg have varied from 24 percent to 88 percent, while Ebola case fatality rates have varied from 25 percent to 90 percent.
- Outbreak warning: Case of deadly EBOLA-LIKE virus with no treatment or vaccine reported
You can unsubscribe at any time. More info The Marburg virus is similar to Ebola, the haemorrhagic fever that left more than 10,000 people dead in the mid-2010s and spread around the world via air ...
Go deeper with Google Headlines on:
Ebola vaccine
Go deeper with Bing News on:
Ebola
- First Infant Dies From Marburg Outbreak, Virus Related to Ebola
The fourth victim was a 14-month-old boy, making it the first infant death caused by this latest Marburg outbreak. The health service explained that the infant was, in fact, the son of the 26-year-old ...
- Toddler dies of Ebola-like disease
Outbreak in Ghana of the Marburg virus, which has a death rate of up to 88 per cent and no known treatments, shows epidemic ‘potential’ ...
- Secop unveils ‘ultra-low’ temp compressor
German manufacturer’s new mobile cooling system enables the safe transportation of COVID-19 and Ebola vaccines regardless of ambient temperatures.
- Child dies of Marburg virus in Ebola-like disease outbreak with symptoms shared
Three people have now died from the Ebola-like Marburg virus in Ghana - which has never experienced an outbreak before - with hundreds now quarantined with the killer disease ...
- Child infected with Ebola-like Marburg virus dies in Ghana
The death brings the total number of fatalities in the country to three since Ghana registered its first ever outbreak of the disease last month. The outbreak is only the second in West Africa. The ...